Logo

Belgian Firm Galapagos Genomics to Build Adenoviruses for Bayer

Jul 10, 2002

NEW YORK, July 10 - Belgian genomics firm Galapagos Genomics said today it will use its PhenoSelect gene-expression tool to build recombinant adenoviruses for Bayer.

 

Through the deal, an expansion of an agreement signed in June 2001, Galapagos will help Bayer perform in vivo validation studies based  on its undisclosed human genes. The drug giant said it plans to use the adenoviruses to express newly found genes in animal models to study corresponding proteins.

 

Click here for more information.

Breaking News
The Scan

Gone, But Now Reconstructed SARS-CoV-2 Genomes

In a preprint, a researcher describes his recovery of viral sequences that had been removed from a common database.

Rare Heart Inflammation Warning

The Food and Drug Administration is adding a warning about links between a rare inflammatory heart condition and two SARS-CoV-2 vaccines, Reuters reports.

Sandwich Sampling

The New York Times sent tuna sandwiches for PCR analysis.

Nature Papers Describe Gut Viruses, New Format for Storing Quantitative Genomic Data, More

In Nature this week: catalog of DNA viruses of the human gut microbiome, new dense depth data dump format to store quantitative genomic data, and more.